Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥501m2023-01-01 → 2023-06-30Cons.Net sales
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Operating income−¥864m2023-01-01 → 2023-06-30Cons.Operating income
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥868m2023-01-01 → 2023-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Profit before tax−¥869m2023-01-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥886m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Net income−¥886m2023-01-01 → 2023-06-30Cons.Profit loss
Total assets¥3.7bnat 2024-06-30Cons.Assets
Total assets¥4.3bnat 2023-12-31Cons.Assets
Total assets¥4.6bnat 2023-06-30Cons.Total assets (5-year summary)
Total liabilities¥470mat 2024-06-30Cons.Liabilities
Total liabilities¥472mat 2023-12-31Cons.Liabilities
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31Cons.Net assets
Net assets / equity¥4.1bnat 2023-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.0bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥2.9bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31dCons.Cash and cash equivalents
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥939m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11m2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.2bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-53.812023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.9%at 2023-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥169m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 417
ItemContextValueUnit
Valuation and translation adjustmentsPrior1YearInstant48986000JPY
Valuation and translation adjustmentsCurrentQuarterInstant116635000JPY
Net assetsPrior1YearInstant3877535000JPY
Net assetsCurrentQuarterInstant3215316000JPY
Liabilities and net assetsPrior1YearInstant4349891000JPY
Liabilities and net assetsCurrentQuarterInstant3685650000JPY
Net salesPrior1YTDDuration500570000JPY
Net salesCurrentYTDDuration315642000JPY
Cost of salesPrior1YTDDuration82684000JPY
Cost of salesCurrentYTDDuration82630000JPY
Gross profitPrior1YTDDuration417886000JPY
Gross profitCurrentYTDDuration233012000JPY
Selling general and administrative expensesPrior1YTDDuration1281582000JPY
Selling general and administrative expensesCurrentYTDDuration1328013000JPY
Operating incomePrior1YTDDuration-863696000JPY
Operating incomeCurrentYTDDuration-1095000000JPY
Interest income noiPrior1YTDDuration84000JPY
Interest income noiCurrentYTDDuration2543000JPY
Dividends income noiPrior1YTDDuration211000JPY
Dividends income noiCurrentYTDDuration219000JPY
Foreign exchange gains noiPrior1YTDDuration2029000JPY
Foreign exchange gains noiCurrentYTDDuration27718000JPY
Other noiPrior1YTDDuration104000JPY
Other noiCurrentYTDDuration2395000JPY
Non operating incomePrior1YTDDuration2430000JPY
Non operating incomeCurrentYTDDuration32877000JPY
Interest expenses noePrior1YTDDuration1695000JPY
Interest expenses noeCurrentYTDDuration1726000JPY
Guarantee commission noePrior1YTDDuration477000JPY
Guarantee commission noeCurrentYTDDuration198000JPY
Stock issuance cost noePrior1YTDDuration4966000JPY
Stock issuance cost noeCurrentYTDDuration23109000JPY
Non operating expensesPrior1YTDDuration7139000JPY
Non operating expensesCurrentYTDDuration25033000JPY
Ordinary incomePrior1YTDDuration-868405000JPY
Ordinary incomeCurrentYTDDuration-1087156000JPY
Impairment loss elPrior1YTDDuration984000JPY
Impairment loss elCurrentYTDDuration4228000JPY
Extraordinary lossPrior1YTDDuration984000JPY
Extraordinary lossCurrentYTDDuration4228000JPY
Income before income taxesPrior1YTDDuration-869389000JPY
Income before income taxesCurrentYTDDuration-1091384000JPY
Income taxes currentPrior1YTDDuration16275000JPY
Income taxes currentCurrentYTDDuration2785000JPY
Income taxes deferredPrior1YTDDuration-56000JPY
Income taxes deferredCurrentYTDDuration-52000JPY
Income taxesPrior1YTDDuration16218000JPY
Income taxesCurrentYTDDuration2733000JPY
Profit lossPrior1YTDDuration-885608000JPY
Profit lossCurrentYTDDuration-1094118000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass